Annual Congress Berlin 2001

Saturday, 22.09.2001
Sunday, 23.09.2001
Monday, 24.09.2001
Tuesday, 25.09.2001
Wednesday, 26.09.2001

Citations should be made in the following way: Authors. Title. Eur Respir J 2004; 18: Suppl. 33, abstract number.

Material from 2001:

3025 Abstracts

Material from 2001: Show

Management of LRTI: clinical and outcomes assessment

Oral Presentation
Chairs: M. Cazzola (Napoli, Italy), S. Hill (Birmingham, United Kingdom)

Download all media

Differences in pneumonia death (PD) rates between European Union (EU) countries A. Simpson, J. C. G. Simpson, M. A. Woodhead (Manchester, United Kingdom)
Predictor clinical factors of length of stay in community-acquired pneumonia. A multiple regression analysis R. Menéndez, D. Ferrando, J. M. Vallés, E. Martínez, S. Reyes (Valencia, Spain)
Community-acquired pneumonia in the elderly: Spanish multicentre study J. Aspa, R. Zalacain, R. Celis, A. Torres, J. Blanquer, On behalf of the Working Group Pneumonia in the Elderly (Madrid, Spain)
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen A. Torres, J. F. Muir, P. P. Sagnier, I. Duprat-Lomon, R. Kubin, G. Höffken (Barcelona, Spain; Rouen, France; Slough, United Kingdom; Wuppertal, Dresden, Germany)
Sputum bacteriology in acute COPD exacerbations: correlation with FEV₁ deterioration M. Ferdoutsis, E. Vakouti, G. Meletis, M. Christodoulou, G. Pitsidianakis, K. Antoniou, G. Patsourakis, N. Bachlitzanakis (Crete, Greece)
May the value of FEV1 be helpful in the choice of the antibiotic therapy in acute exacerbation of COPD? M. Biagini, M. Rossi (Arezzo, Italy)
FEV1 is a sensible marker of healing after antibiotic treatment in severe COPD outpatients affected with AECB T. Camnasio, C. Rampoldi, L. Chiesa, V. Frigo, G. Negretto, R. Raccanelli, F. Rodi, S. Damato (Seregno, Italy)
Poor quality of life is associated with frequent exacerbations in moderate-to-severe COPD patients M. Miravitlles, C. Murio, R. Lamarca, J. L. Alvarez-Sala, F. Ros, J. F. Masa, H. Verea, R. Zalacain, R. Vidal, On behalf of the IMPAC Study Group (Barcelona, Spain)